Navigation Links
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Date:6/8/2009

EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.

Dr. Baldino brings several decades of pharmaceutical and health care industry experience and leadership to ViroPharma. He is the chief executive officer and chairman of the board of directors of Cephalon Inc., an international biopharmaceutical company in Chester County, Pennsylvania. Dr. Baldino founded Cephalon in 1987 and has served as chief executive officer and director since its inception.

Prior to joining Cephalon, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research. Dr. Baldino received his Ph.D. in pharmacology from Temple University.

Dr. Baldino previously served as a member of ViroPharma's board of directors from 1996 to 2006.

"We are extremely pleased to welcome Frank Baldino, one of the most successful biopharmaceutical entrepreneurs, back to our board of directors," commented Vincent Milano, president and chief executive officer of ViroPharma. "For over a decade, Frank was an extraordinarily valuable member of our board, and we benefited significantly from his guidance and his experience. He brings to ViroPharma a wealth of experience in virtually any issue that a growing pharmaceutical company might encounter, and we are thrilled to welcome him back to our board."

"I am excited to have the opportunity to serve again on the board of directors of
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
2. ViroPharma to Present at Two May Healthcare Conferences
3. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
4. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
5. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
6. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
7. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. ViroPharma Provides Update on Vancocin(R)
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
11. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ease the problem, researchers say , , MO...p their anger over unfair treatment at work could ...ates. , Men who consistently failed to express ...er or supervisor were more than twice as likely to...ose who vented their anger, claims a report in the...
(Date:11/23/2009)...alsintheRecommendedPriorityGroups ,, HARRISBURG...tofHealthannouncedtodaytheywillconductthreeadditio...inDelaware,Lancaster,andLehighcountiesonTuesday,No...isteredforfreetoindividualsintherecommendedtargetg...epartmentasksthatonlyindividualsinthefollowinggrou...
(Date:11/23/2009)... survivors treated with chemotherapy suffer insomn...nditions, hindering patients, ability to fully rec... Rochester Medical Center. , A study of 823 canc... at nearly three times the rate of the general pop... patients and those with lung and breast cancers, ...
(Date:11/23/2009)...f-its-kind consensus statement on diabetes surgery...ry . The report illustrates the findings of the fi... Surgery Summit (DSS) -- where an international gr... agreed on a set of evidence-based guidelines and ...udy of gastrointestinal surgery to treat type 2 di...
(Date:11/23/2009)... who reined in their hypertension, study found, ,...igh blood pressure is better controlled by doctor-...ors and pharmacists working alone, a new study sho...edications are intensified, dosages increased, med...ter, a professor in the University of Iowa College...
Breaking Medicine News(10 mins):Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 4Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 5Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3
...bs to Lodi , , LODI, Calif., Dec. 4 Moving f...ommunity, Blue Shield of California celebrates the...ervice center today with a ribbon-cutting ceremony...es working in customer service, claims and members...
... of the findings of its 5th,International Nutritio...,nutrition and its importance in elite physical pe...ram on the specific nutritional needs of athletes,...ich,should lead to a new generation of personalize...
...ma who are exposed to environmental tobacco smoke ...depression and other behavioral problems, accordin... Medical Center. , In a study posted online ahead...vels, but they added even low levels of tobacco sm...
...rs, LLC, a specialty,bank consulting firm, has mov...rk (JHFN). Through Empire Financial Partners, an i...k in Buffalo, NY, they will offer bank owned life,...o offer this specialized knowledge and,experience ...
...ch as in the skin, intestinal mucosa or blood, hav... to function, a steady replenishment of specialize...alled "adult" stem cells also known as tissue stem...ective tissue a property called pluripotency. Se...
...giCount Medical,Inc., a division of Patient Safety...day announced that it has joined The Leapfrog Grou... create a safer, higher quality health care,system...o an affiliation with,Leapfrog. We share a common ...
Other Medicine News:Health News:Blue Shield of California Celebrates Completion of New Lodi Campus 2Health News:Blue Shield of California Celebrates Completion of New Lodi Campus 3Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 2Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 3Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 3Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 2Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 3Health News:Dormant stem cells for emergencies 2Health News:Dormant stem cells for emergencies 3Health News:SurgiCount Medical Joins The Leapfrog Group 2
(Date:11/23/2009)....23/PRNewswire/--LigonDiscovery,Inc.,whichusesprop...sagainsthigh-valuetargets,todayannouncedtheappoint...sLigon,sExecutiveChairmanoftheBoard. ,, "I,mver...theBoard,"saidPatrickKleyn,Ligon,schiefexecutiveof...enceinthelifesciencesindustry--particularlyhislead...
(Date:11/23/2009)...ovalsoftwonewtherapiesforNon-Hodgkin,sLymphomas(NH...ofatumumab(Azerra(TM),GlaxoSmithKline)asatherapyop...andromidepsin(Istodax(R),GloucesterPharmaceuticals...lllymphoma(CTCL). ,, FORTWASHINGTON,Pa.,Nov.23/...romptedtheNationalComprehensiveCancerNetwork( NCCN...
(Date:11/23/2009)...wswire/--Reportlinker.comannouncesthatanewmarketre...calNonwovenDisposables-AWorldwideMarketReview ,...Nonwoven-Disposables---A-Worldwide-Market-Review.h...m_campaign=prnewswire ,, Withincreaseinrang...healthcareandhospitalfacilities,nonwovenshasemerge...
Breaking Medicine Technology:Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8Arcadian Health Names Rick Click as New Chief Information Officer 58491 1Arcadian Health Names Rick Click as New Chief Information Officer 58491 2Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6 2009 58489 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 3Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 4Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 5Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 6
...x to Fund Human Clinical Trials, MINNEAPOLIS, Oct... $20 million Series B financing. Co-Founded in Jul...utonix is a medical device company,focused on the ...alloon,angioplasty technology for the treatment an...nosis caused by atherosclerosis. Lutonix,s drug co...
...es for the most common, pathogens, including meth...EINACH, Switzerland, Oct. 26 Arpida (SWX:,ARPN) t...al Phase III,clinical trials at the 48th Interscie...erapy (ICAAC)/Infectious Diseases Society of Ameri...n these studies, intravenous iclaprim, a,novel ant...
Other Medicine Technology:Lutonix Inc. Announces $20 Million Series B Financing 2Lutonix Inc. Announces $20 Million Series B Financing 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7
Replacement Bulb: HBO 50W/3
Replacement Bulb: FCS
Replacement Bulb: ELC 64653HLX
Replacement Bulb: EFR
Medicine Products: